New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:44 EDTSNSSSunesis raises $43M in common stock and warrants offering
Sunesis announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0M. Cowen and Company, LLC and Cantor Fitzgerald & Co. are acting as Joint Book-Running Managers in this offering.
News For SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:03 EDTSNSSSunesis announces EU patent covering vosaroxin, cytarabine combination
Sunesis Pharmaceuticals announced that the European Patent Office, or EPO, has granted European Patent No. 2 049 109 B1, claiming certain combined uses of vosaroxin and cytarabine, at doses of 10-120 mg/m2 and 5-1500 mg/m2, respectively, for the treatment of acute myelogenous leukemia and acute myeloblastic leukemia. The patent further provides for combinations of vosaroxin and cytarabine with other therapies, such as radiation, or other chemotherapeutics, including anti-cancer agents, in hematologic disorders, whether administered simultaneously or sequentially. Sunesis is proceeding to validate this patent in multiple EPO member states. The resulting national patents would expire in the third quarter of 2027, but could be eligible for supplementary patent term in EPO member states beyond this date. Related patent applications are pending in several countries, including the United States and Japan.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use